TargeTrust Biotech.

Real Early Cancer Screening, Detecting Cancer Therapy Resistance & Guiding Precision Dosing in Real-Time, and Universal Cancer-Specific Drugs 

 # Vision and Mission:

     We invent a method to produce universal cancer-specific drugs. Our products can greatly reduce the global cancer problem. The world’s only methods to: 

1. Produce universal cancer-specific drugs and high-resolution tumor imaging agents.

2. Screen multiple early cancer to cut tumor away, making cancer cured easily.

3. Detect cancer therapy resistance in real-time. Guide correct therapy. Prevent patients from taking ineffective drugs.

4. Guide precision dosing in real-time. Reduce drug side-effects.

5. Detect early cancer relapse to timely treat it.

6. Make real-time cancer action detection possible.

# Problems in Caner Treatment:

1. Most cancers are detected too late by current methods, making cancer hard to treat.

2. Therapy resistance:30～70% treating drugs become ineffective; patients take ineffective drugs; delay therapy; hightly lethal.

3. Drug side-effects: Patients uncomfortable; may disrupt therapy; cause other diseseases; sometime lethal.

4. Current methods (CT, MRI, PET, CTC & ctDNA liquid biopsies, traditional biomarkers, CancerSEEK, Grail MCED Test) assay cancer and cancer therapy response at cancer progression stage (increased tumor size, tumor invade other organs), these take many months, too late, delaying therapy. The sensitivities of current methods in detecting early stage cancer are low.

 # Our Invention-1:  

     Tumor signal transductions stimulate cancer progression, it takes less than 1 hour and continuously. We create a novel medical field "Tumor Signal Transduction-Liquid Biopsy" to assay tumor cellular signal transduction in blood. It is the world's only method to assay cancer initiation, cancer progression, therapy resistance, and guide precision dosing, in real-time. It makes real-time cancer action detection possible. 

# Our Invention-2:   

     Universal cancer-specific drugs can increase the chance of completely killing all tumors in the body of a patient, increasing therapy efficacy. 

      We invent a method to produce universal cancer-specific drugs and high-resolution tumor imaging agents to achieve universal precision cancer therapy. 

       Our inventions lead the future of cancer care, opening up a huge new pharmaceutical industry.

Invention-1: Tumor Signal Transduction-Liquid Biopsy

Clinical Trials

Competitive Analysis

1. Grail MCED Test and CancerSEEK  can detect 50 or 8 cancer types by assaying blood ctDNA. The sensitivity for stage I cancer detection range from 12% ～ 39% .

2.  Cancer assay with CancerSEEK and Grail MCED Test  are too late and delay therapy, because presence or increased ctDNA (circulating tumor DNA) indicate tumor growth, invasion, and therapy resistance occurred a long time ago. 

3. CancerSEEK and Grail MCED Test are a lab service, not a sellable product, thus are not widely available. 

Invention-2:  Universal Cancer-Specific Biomarker    

         We invent a method to produce universal cancer-specific drugs.

 p-CSE1L:

(1)  It is significantly expressed in most cancer types, essential for cancer cell survival & proliferation.

(2)  It accumulates in tumor cell membrane and vesicle membrane.

(3)  Tumors have oncogenes which result in CSE1L phosphorylation and high tumor p-CSE1L.  

Normal tissues  don’t express oncogene, p-CSE1L is undetectable

(4)  CSE1L-imaging agent can target tumor. 

Utility: Produce universal cancer-specific drugs and imaging agents

1. Targeted contrast agent for image-guided precision cancer surgery.

2. Targeted imaging agent for precision radiotherapy.

3. Targeted antibody-contrast agent for MRI high-resolution tumor imaging to detect currently undetectable occult small metastases.

4.    Targeted antibody-contrast agent for PET high-resolution tumor imaging to detect currently undetectable occult small metastases.

5. Antibody-drug conjugates (ADC), antibody radiodrug conjugate (ARC), and peptide-drug conjugates.

6. Bispecific antibody for cancer immunotherapy.

7. Targeted liposome drugs.

8. Nanoparticles for targeted magnetic hyperthermia therapy.

Advantages of Universal Cancer-Specific Drugs

1.   All tumors have the biomarker, thus, a universal cancer-specific drug can increase the chance of completely killing all tumors in the body of a patient, increasing therapy efficacy, reducing therapy resistance, disease relapse, and drug side-effects.

2.   Simplify cancer therapy, no need to analyze the complex tumor genetic mutation profile to select a matching traditional drug for a patient.

3.   Reduce the timelines, costs, and improve drug accessibility in comparison with that of the high attrition rates of new drug candidates in developing traditional drugs.

4.   Simplify drug development; no need to develop each drug to each cancer type on by one, reducing the works and costs of drug development and drug price.

5.   By developing drugs based on existing known universal cancer-specific biomarkers rather than starting from invoking accidental luck to screen candidate new traditional drugs, pharmaceutical companies can lower the finance and barriers of drug development and drug price.

Patents

Contact: jiangmwd@gmail.com